Table 1.
Participant Characteristics
| Variable | SCZ (n = 29) (Mean ± SD) |
HC (n = 23) (Mean ± SD) |
t/χ2 | P |
|---|---|---|---|---|
| Age (y) | 43.6±12.6 | 43.5±13.1 | 0.03 | .978 |
| Sex (male/female) | 20/9 | 18/5 | 0.56 | .453 |
| Education (y) | 13.6±1.9 | 16.4±2.6 | −4.41 | <.001 |
| Parental education (y) | 14.7±3.7 | 15.0±2.8 | −0.37 | .715 |
| Age of onset (y) | 19.8±7.0 | — | — | — |
| Duration of illness (y) | 23.8±13.1 | — | — | — |
| SAPS | 5.6±3.6 | — | — | — |
| SANS | 4.5±3.1 | — | — | — |
| CPZeq (mg daily) | 428±489 | — | — | — |
| Dichotomous gaze perception | 2.23±0.68 | 2.65±0.48 | −2.47 | .017 |
| MSCEITa | 90.8±18.4 | 106.5±17.4 | −2.80 | .008 |
Note: SAPS, sum of global subscores on the Scale for the Assessment of Positive Symptoms31; SANS, sum of global scores of the flat affect, alogia, apathy, and anhedonia subscales of the Scale for the Assessment of Negative Symptoms32; CPZeq, antipsychotic dose in chlorpromazine equivalent mg daily; MSCEIT, Age- and gender-adjusted total score on the Mayer-Salovey-Caruso Emotional Intelligence Test.25
aDue to missing data, MSCEIT overall score was available for only 22 SCZ and 19 HC.